Entero Therapeutics, Stock Market Value
| ENTO Stock | 0.42 0.02 5.00% |
| Symbol | Entero |
Entero Therapeutics, Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.04) | Return On Assets (0.27) | Return On Equity (0.15) |
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Entero Therapeutics, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Entero Therapeutics,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Entero Therapeutics,.
| 08/23/2024 |
| 11/21/2024 |
If you would invest 0.00 in Entero Therapeutics, on August 23, 2024 and sell it all today you would earn a total of 0.00 from holding Entero Therapeutics, or generate 0.0% return on investment in Entero Therapeutics, over 90 days. Entero Therapeutics, is related to or competes with ZyVersa Therapeutics, Sonnet Biotherapeutics, Zura Bio, Phio Pharmaceuticals, Transcode Therapeutics, and Quoin Pharmaceuticals. Entero Therapeutics, is entity of United States More
Entero Therapeutics, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Entero Therapeutics,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Entero Therapeutics, upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 8.73 | |||
| Information Ratio | 0.0721 | |||
| Maximum Drawdown | 90.66 | |||
| Value At Risk | (13.33) | |||
| Potential Upside | 24.44 |
Entero Therapeutics, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Entero Therapeutics,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Entero Therapeutics,'s standard deviation. In reality, there are many statistical measures that can use Entero Therapeutics, historical prices to predict the future Entero Therapeutics,'s volatility.| Risk Adjusted Performance | 0.0693 | |||
| Jensen Alpha | 0.7147 | |||
| Total Risk Alpha | (0.44) | |||
| Sortino Ratio | 0.106 | |||
| Treynor Ratio | 0.292 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Entero Therapeutics,'s price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Entero Therapeutics, Backtested Returns
Entero Therapeutics, appears to be risky, given 3 months investment horizon. Entero Therapeutics, secures Sharpe Ratio (or Efficiency) of 0.0542, which denotes the company had a 0.0542% return per unit of risk over the last 3 months. By reviewing Entero Therapeutics,'s technical indicators, you can evaluate if the expected return of 0.67% is justified by implied risk. Please utilize Entero Therapeutics,'s Mean Deviation of 7.52, downside deviation of 8.73, and Coefficient Of Variation of 1257.98 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Entero Therapeutics, holds a performance score of 4. The firm shows a Beta (market volatility) of 3.46, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Entero Therapeutics, will likely underperform. Please check Entero Therapeutics,'s value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Entero Therapeutics,'s price patterns will revert.
Auto-correlation | -0.61 |
Very good reverse predictability
Entero Therapeutics, has very good reverse predictability. Overlapping area represents the amount of predictability between Entero Therapeutics, time series from 23rd of August 2024 to 7th of October 2024 and 7th of October 2024 to 21st of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Entero Therapeutics, price movement. The serial correlation of -0.61 indicates that roughly 61.0% of current Entero Therapeutics, price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.61 | |
| Spearman Rank Test | -0.51 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Entero Therapeutics, lagged returns against current returns
Autocorrelation, which is Entero Therapeutics, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Entero Therapeutics,'s stock expected returns. We can calculate the autocorrelation of Entero Therapeutics, returns to help us make a trade decision. For example, suppose you find that Entero Therapeutics, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Entero Therapeutics, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Entero Therapeutics, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Entero Therapeutics, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Entero Therapeutics, stock over time.
Current vs Lagged Prices |
| Timeline |
Entero Therapeutics, Lagged Returns
When evaluating Entero Therapeutics,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Entero Therapeutics, stock have on its future price. Entero Therapeutics, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Entero Therapeutics, autocorrelation shows the relationship between Entero Therapeutics, stock current value and its past values and can show if there is a momentum factor associated with investing in Entero Therapeutics,.
Regressed Prices |
| Timeline |
Pair Trading with Entero Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entero Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entero Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving together with Entero Stock
Moving against Entero Stock
| 0.67 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.62 | KURA | Kura Oncology | PairCorr |
| 0.55 | TERN | Terns Pharmaceuticals | PairCorr |
| 0.52 | XFOR | X4 Pharmaceuticals | PairCorr |
| 0.45 | KTTA | Pasithea Therapeutics | PairCorr |
The ability to find closely correlated positions to Entero Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entero Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entero Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entero Therapeutics, to buy it.
The correlation of Entero Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entero Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Entero Therapeutics, Correlation, Entero Therapeutics, Volatility and Entero Therapeutics, Alpha and Beta module to complement your research on Entero Therapeutics,. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Entero Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.